Superbrewed Food’s SB1 is a whole-food protein ingredient made by biomass fermentation of a non-GMO bacterium, designed for use at 10 to 20 grams per serving. On 19 August the company launched Thryvia, made from the same protein-rich bacterium, intended for inclusion at around 200 milligrams per serving.
That is a reduction in dose of 50 to 100 times. Same organism, same fermentation, same manufacturing partner — and between fifty and a hundred times more servings out of every kilogram produced.
Cofounder Bryan Tracy is unusually direct about why. Asked whether this was a retreat from protein, he told AgFunderNews:
“This isn’t a move away from the protein opportunity. Customer interest and demand for our postbiotic cultured protein (SB1) remain strong. The constraint is capacity: raising the capital required to build substantially beyond what our Döhler partnership can currently produce remains a real challenge.”
And then, the operative sentence:
“We can support multiple significant customer launches and their growth with our existing production footprint rather than waiting for a major capacity expansion.”
This is the clearest statement we have seen from an operating fermentation company that the binding constraint on a bulk protein business is neither demand nor science, but the cost of tanks — and the first we have seen where the response was to re-engineer the dose rather than the plant.
The arithmetic of a dose cut
The reason this is a capacity strategy and not merely a product launch becomes obvious when the numbers are put on a per-tonne basis.
| SB1 | Thryvia | Ratio | |
|---|---|---|---|
| Stated inclusion per serving | 10–20 g | ~200 mg | 50× to 100× lower |
| Servings per kg of ingredient | 50 to 100 | ~5,000 | 50× to 100× more |
| Servings per tonne of ingredient | 50,000 to 100,000 | ~5,000,000 | 50× to 100× more |
Servings per kilogram and per tonne are our arithmetic from the stated inclusion rates, not figures published by Superbrewed.
A company that cannot raise capital to expand a plant has three options: raise the price, raise the yield, or lower the quantity each customer needs. The first two are hard and slow. The third is a formulation decision, and it can be made inside an existing footprint.
The trade-off is that a 200 mg ingredient cannot be sold on macronutrient grounds. Nobody buys 200 mg for its protein content. So the value proposition has to move from nutrition to function — which is precisely what Thryvia does, repositioning as a “postbiotic” for digestive and immune support.
Practical consequence: for anyone assessing a fermentation ingredient supplier, ask what the inclusion rate is before asking what the capacity is. A supplier with 1,000 tonnes of capacity selling at 200 mg per serving has a fundamentally different capital requirement, and a fundamentally different revenue-per-tonne, from one selling at 15 grams. Capacity figures in tonnes are not comparable across ingredients with different doses — a point we have made repeatedly about stated capacity bases and which applies with more force here.
What the product is
Thryvia is produced from a heat-killed, non-viable Clostridium tyrobutyricum strain — the company’s own page identifies it as strain ASM#19 — and is shelf-stable at room temperature. Because the cells are inert, its activity does not depend on maintaining viability through manufacturing, distribution and shelf life.
That is the genuine formulation argument, and it is not a trivial one. Tracy’s framing:
“Probiotics can introduce stability, processing and cold-chain constraints and generally won’t survive processes such as UHT. … Prebiotics can require multiple gram-level inclusion, which can create formulation and sensory challenges.”
An inert ingredient at 200 mg goes into capsules, powders, gummies, bars, foods and beverages, including UHT-processed shelf-stable formats, without cold chain. Existing postbiotics on the market include ADM’s heat-treated BPL1 and Cargill’s EpiCor yeast fermentate; Tracy’s claim to differentiation is compositional: “bioactivity comes from proteins that are part of the biomass. Several postbiotics in the market are based on beta-glucans, metabolites, and secondary metabolites. I’m not aware of postbiotics in the market that are based on proteins.”
We have not verified the claim that no protein-based postbiotic exists on the market, and record it as the company’s assertion.
The company says the bacterium meets the ISAPP consensus definition of a postbiotic — “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host”. The second half of that definition does real work, and it is where the evidence question sits.
Regulatory status is cleaner than the evidence base
The regulatory position is genuinely well advanced, and this is the part of the story that most supports the pivot.
| Item | Status | Note |
|---|---|---|
| US food and dietary supplements | GRAS “no questions” letter, GRN 1129 | Company states the filing covers broad use across food and supplement applications |
| US companion animal | Separate pathway | Company states this is “addressed on a formulation-by-formulation basis” |
| EU pet market | “Commercially available for the EU pet market today” | Company statement |
| EFSA QPS | Clostridium tyrobutyricum “has been recommended by EFSA experts for inclusion on the Qualified Presumption of Safety (QPS) list” | Company statement; a recommendation is not the same as market authorisation |
| EU novel food and UK FSA | “Safety evaluations are underway” | Company statement; no application reference published |
The company is also candid, on its own page, that the GRAS filing does not carry the health claims: “The GRAS filing establishes Thryvia’s safety as a food ingredient. Specific immune-support, digestive-support, or postbiotic health claims require separate claims substantiation beyond the GRAS filing.”
That is the correct statement of US law, and it is more than many ingredient pages say. It also sets up the tension in the next section.
The evidence gap the company names itself
Superbrewed’s Thryvia page lists, under “Clinical”, the claims “Clinically studied to support digestive health” and “Clinically studied to support general wellness.”
The consumer data underneath those claims comes from what the page calls “a decentralized perception study” over four weeks: 65% reported less digestive discomfort after consuming dairy products, 76% said their stomach felt more at ease throughout the day, 70% reported less abdominal discomfort or cramping, and 65% each reported more enjoyable mealtimes, generally feeling better, and that they would recommend it.
The same page carries this footnote: “Consumer-reported outcomes from a decentralized perception study and a blinded consumer preference survey. Perceptions are self-reported and are not a measure of clinical efficacy.”
And Tracy, to AgFunderNews, is more explicit still:
“But substantiating specific structure/function claims [such as supports gut health] ultimately requires appropriately designed well-powered, randomized, double-blind, placebo-controlled human trials. We are building this complete evidence package now.”
So the company’s own chief scientist-founder states that the trials required to substantiate a gut-health claim are in progress rather than complete, while the marketing page describes the ingredient as “clinically studied to support digestive health”. Both statements can be literally true — a perception study is a study involving humans — and the page does disclaim clinical efficacy in its footnote. But a formulator reading the claims block and a formulator reading the footnote will come away with different views of the evidence.
The mechanistic and animal work is at an earlier stage by design: third-party preclinical research demonstrating “targeted activation of innate immune receptors (TLR2, TLR5, and NOD2)” and controlled animal studies described as providing “translational evidence of intestinal and host-response activity”. Tracy is careful about what each tier buys: “Mechanistic and translational studies… help us understand the biology and establish plausible modes of action.”
Practical consequence: if you are evaluating Thryvia for a finished product, ask for the protocol and results of the four-week perception study, and ask which randomised controlled trials are running, at what dose, with what primary endpoint, and when they read out. The dose matters especially: a mechanism demonstrated in vitro says nothing about whether 200 mg is the efficacious amount in a human. The company has not published a dose-ranging rationale for the 200 mg figure.
The counter-argument
The uncharitable reading of this launch — a bulk protein company that cannot fund a plant retreating into a higher-margin, lower-volume supplement ingredient — is available, and we do not think it is the whole story.
Three points against it. First, Tracy did not hide the capacity constraint; he volunteered it, which is not the behaviour of a company dressing up a retreat. Second, the postbiotic positioning is not a marketing veneer over a protein: the ingredient has a different formulation, is inert by design, and addresses a genuinely different customer need. Third, the overlap is commercially coherent rather than cannibalising — “A majority of potential SB1 [protein] customers are also very interested in Thyrvia”, Tracy says, and digestive and immune support do sit naturally alongside protein nutrition.
There is also a serious strategic argument here that deserves to be stated properly. If raising several hundred million dollars for fermentation capacity is currently very hard — and the evidence from Believer Meats’ plant finding no buyer and from the sector’s broader capital narrowing suggests it is — then building a product line that monetises an existing footprint fifty-fold is a rational allocation of scarce capital, not a concession. Companies that wait for the capacity round may not get one.
The honest summary is that this is a sensible response to a real constraint, and that the evidence base for the new product is at an earlier stage than the marketing language implies.
What we could not establish
- Superbrewed’s actual production capacity. Neither Superbrewed nor Döhler has published a volume for the commercial production that began in Europe this year. Our servings-per-tonne arithmetic is therefore a ratio, not an output figure.
- The rationale for 200 mg. No dose-ranging data or justification for the specific inclusion rate has been published. The figure is given as “around 200mg per serving”.
- Whether any randomised controlled trial is registered. Tracy says human studies are “ongoing” and the evidence package is being built. We did not locate a trial registration.
- The date of GRN 1129. AgFunderNews reports the “no questions” letter was issued in 2024; the company page cites GRN 1129 without a date. We have not read the letter itself.
- Whether a protein-based postbiotic already exists on the market. This is the company’s claim, framed as “I’m not aware of”, and we have not tested it.
- Any EFSA novel food or UK FSA application reference. The company says evaluations are “underway”; no application number is published.
- Pricing for either ingredient. Neither SB1 nor Thryvia has a published price, so we cannot say whether revenue per tonne of biomass rises or falls under the new dose.
That last gap is the important one. A 50-to-100× dose reduction increases servings per tonne by the same factor, but says nothing about revenue per tonne unless the price per serving is known. It is entirely possible for a low-dose functional ingredient to be worth more per tonne than a bulk protein, and equally possible for it not to be. Without a price, the capacity argument is directionally clear and financially unquantified.
What to watch
- Whether Superbrewed raises capacity capital anyway. Tracy framed the dose cut as working within the existing footprint “rather than waiting for a major capacity expansion”, not as abandoning one. A subsequent raise would tell us the pivot bought time rather than replaced the plan.
- Whether SB1 customer launches actually happen. The claim is that protein demand “remains strong”. Named commercial launches at 10–20 grams per serving would substantiate it.
- Whether a randomised controlled trial reads out, at what dose. This is the load-bearing item for the whole postbiotic positioning, and the company has committed to it in public.
- Whether other capacity-constrained fermentation companies copy the move. If the low-dose functional pivot becomes a pattern across biomass fermentation, it is evidence that the sector’s bulk-protein thesis is being repriced by the cost of capital rather than by the science — and that would be one of the more consequential shifts on this beat.